Nobuyuki Yamamoto

10PUBLICATIONS

87CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|May 26, 2026

Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Mar 30, 2026

Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Toshiaki Takakura, Ryota Shibaki, Atsushi Washioka

|Jan 13, 2026

Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Glenwood D Goss, Gail E Darling, Virginie Westeel

|Mar 31, 2025

Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

|Sep 01, 2023

Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.

Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi

|Jun 28, 2022

Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori

Pageof 2

Frequent Collaborators

Kazuhiko Nakagawa

Hiroaki Akamatsu

Tetsuya Mitsudomi

Shunichi Sugawara

Yasuhiro Koh

Yuichi Ozawa

Ernest Nadal

Takashi Seto

Hidetoshi Hayashi

Satoru Miura

Frequent Collaborators

Kazuhiko Nakagawa

Hiroaki Akamatsu

Tetsuya Mitsudomi

Shunichi Sugawara